Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery
RecruitingPhase 2
Investigating the Effect of TNX-1900 on Pain Management, Neural and Socio-Emotional Functioning in Patients Undergoing Pituitary Surgery
Who can join
Ages 30 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age: Between 30 to 75 years old. * Consent: Ability to give informed consent. * Language: Proficiency in the English language. * Medical Condition: Diagnosed with a pituitary lesion requiring surgery. * Menopausal Status: Post-menopause for women (at least 1 year since last menstrual period). Exclusion Criteria: * Medication: Individuals on stable doses of psychotropic medication for at least the past six weeks are eligible, excluding those with changes in medication within that timeframe. * Neurological Conditions: A history of seizures, current use of anticonvulsants. * Pregnancy: Currently pregnant, currently lactating, or up to 1-year post partum. * Any history of renal impairment (serum creatinine \>1.2 x ULN) * Any history of hepatic impairment (AST and/or ALT \>2 x ULN) * Surgical History: Any history of previous pituitary surgery procedures * Subjects who require 24-hour coverage with NSAIDs, e.g., arthritis, should not be included in the study. * Any known hypersensitivity to TNX-1900
About the study
This study is testing whether oxytocin can help lessen pain by changing how people process emotions and social experiences. The goal is to better understand how the brain links emotions, relationships, and pain, and whether this connection can be used to improve pain treatment.
What is being tested
- Oxytocin (Low dose) (drug)
- Oxytocin (High dose) (drug)
- Placebo (saline) (drug)
Sponsor: Yale University · Participants: 75 · Started: 2026-11
Contact the study team
- S. Bulent Omay, MD · Phone: 203-737-6885
Official record on ClinicalTrials.gov — NCT07730294
Locations in the U.S.
| Connecticut | Yale University, New Haven |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.